Johnson & Johnson is paying $17.3 billion to buy a company that helps your heart pump blood
At $380 per share in cash, J&J is paying a roughly 50% premium to Abiomed’s closing price on Monday, close to the stock’s 52-week high in November 2021.
At $380 per share in cash, J&J is paying a roughly 50% premium to Abiomed’s closing price on Monday, close to the stock’s 52-week high in November 2021. Read More
